CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RBM39 (ImmuneEditome ID:9584)

1. Gene summary of enriched editing regions for RBM39

check button Gene summary
Gene informationGene symbol

RBM39

Gene ID

9584

GeneSynonymsCAPER|CAPERalpha|FSAP59|HCC1|RNPC2
GeneCytomap

20q11.22

GeneTypeprotein-coding
GeneDescriptionRNA-binding protein 39|CAPER alpha|RNA-binding region (RNP1, RRM) containing 2|coactivator of activating protein-1 and estrogen receptors|epididymis secretory sperm binding protein|functional spliceosome-associated protein 59|hepatocellular carcinoma protein 1|splicing factor HCC1
GeneModificationdate20230517
UniprotIDQ14498;F2Z3E6;G3XAC6;H7BZG3;Q5QP22;A8MYG5;Q5QP23;F8WF24;F2Z2Z5;F8WF73;A0A0U1RQH7;A0A087X122
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr20:35712223-35713652:-ENST00000253363.9ENSG00000131051.19RBM39exonicAluJb,AluSz,AluSpchr20:35712223-35713652:-.alignment
chr20:35712223-35713652:-ENST00000338163.9ENSG00000131051.19RBM39exonicAluJb,AluSz,AluSpchr20:35712223-35713652:-.alignment
chr20:35712223-35713652:-ENST00000361162.9ENSG00000131051.19RBM39exonicAluJb,AluSz,AluSpchr20:35712223-35713652:-.alignment
chr20:35712223-35713652:-ENST00000448303.4ENSG00000131051.19RBM39exonicAluJb,AluSz,AluSpchr20:35712223-35713652:-.alignment
chr20:35712223-35713652:-ENST00000476806.4ENSG00000131051.19RBM39exonicAluJb,AluSz,AluSpchr20:35712223-35713652:-.alignment
chr20:35712223-35713652:-ENST00000528062.6ENSG00000131051.19RBM39exonicAluJb,AluSz,AluSpchr20:35712223-35713652:-.alignment
chr20:35723495-35724184:-ENST00000461283.4ENSG00000131051.19RBM39ncRNA_intronicAluSq2,AluJr4,AluSx1chr20:35723495-35724184:-.alignment
chr20:35723495-35724184:-ENST00000463004.4ENSG00000131051.19RBM39ncRNA_intronicAluSq2,AluJr4,AluSx1chr20:35723495-35724184:-.alignment
chr20:35723495-35724184:-ENST00000490484.5ENSG00000131051.19RBM39ncRNA_intronicAluSq2,AluJr4,AluSx1chr20:35723495-35724184:-.alignment
chr20:35723495-35724184:-ENST00000492779.4ENSG00000131051.19RBM39ncRNA_intronicAluSq2,AluJr4,AluSx1chr20:35723495-35724184:-.alignment
chr20:35723495-35724184:-ENST00000494274.4ENSG00000131051.19RBM39ncRNA_intronicAluSq2,AluJr4,AluSx1chr20:35723495-35724184:-.alignment
chr20:35725753-35727011:-ENST00000461283.4ENSG00000131051.19RBM39ncRNA_intronicAluSc8,AluSq2,AluSxchr20:35725753-35727011:-.alignment
chr20:35725753-35727011:-ENST00000463004.4ENSG00000131051.19RBM39ncRNA_intronicAluSc8,AluSq2,AluSxchr20:35725753-35727011:-.alignment
chr20:35725753-35727011:-ENST00000481037.4ENSG00000131051.19RBM39ncRNA_intronicAluSc8,AluSq2,AluSxchr20:35725753-35727011:-.alignment
chr20:35725753-35727011:-ENST00000492779.4ENSG00000131051.19RBM39ncRNA_intronicAluSc8,AluSq2,AluSxchr20:35725753-35727011:-.alignment
chr20:35728784-35729042:-ENST00000461283.4ENSG00000131051.19RBM39ncRNA_intronicAluSg,AluSxchr20:35728784-35729042:-.alignment
chr20:35728784-35729042:-ENST00000463004.4ENSG00000131051.19RBM39ncRNA_intronicAluSg,AluSxchr20:35728784-35729042:-.alignment
chr20:35728784-35729042:-ENST00000481037.4ENSG00000131051.19RBM39ncRNA_intronicAluSg,AluSxchr20:35728784-35729042:-.alignment
chr20:35728784-35729042:-ENST00000492779.4ENSG00000131051.19RBM39ncRNA_intronicAluSg,AluSxchr20:35728784-35729042:-.alignment
chr20:35736664-35738142:-ENST00000442447.4ENSG00000131051.19RBM39ncRNA_intronicAluSg4,AluSq2,AluSc,AluY,AluSc8chr20:35736664-35738142:-.alignment
chr20:35736664-35738142:-ENST00000461283.4ENSG00000131051.19RBM39ncRNA_intronicAluSg4,AluSq2,AluSc,AluY,AluSc8chr20:35736664-35738142:-.alignment
chr20:35736664-35738142:-ENST00000463004.4ENSG00000131051.19RBM39ncRNA_intronicAluSg4,AluSq2,AluSc,AluY,AluSc8chr20:35736664-35738142:-.alignment
chr20:35736664-35738142:-ENST00000477334.1ENSG00000131051.19RBM39ncRNA_intronicAluSg4,AluSq2,AluSc,AluY,AluSc8chr20:35736664-35738142:-.alignment
chr20:35736664-35738142:-ENST00000481037.4ENSG00000131051.19RBM39ncRNA_intronicAluSg4,AluSq2,AluSc,AluY,AluSc8chr20:35736664-35738142:-.alignment
chr20:35736664-35738142:-ENST00000487604.1ENSG00000131051.19RBM39ncRNA_intronicAluSg4,AluSq2,AluSc,AluY,AluSc8chr20:35736664-35738142:-.alignment


Top

2. Tumor-specific enriched editing regions for RBM39


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr20:35712223-35713652:-BRCAEER6.9532e-09image
ENSG00000131051.19,RBM39BRCAEAG4.2128e-07image
chr20:35712223-35713652:-KIRCEER4.6004e-02image
chr20:35712223-35713652:-LUADEER1.9001e-02image
ENSG00000131051.19,RBM39LUSCEAG8.4322e-03image
chr20:35712223-35713652:-THCAEER1.3138e-10image
ENSG00000131051.19,RBM39THCAEAG2.5163e-10image
chr20:35712223-35713652:-UCECEER6.6802e-03image
ENSG00000131051.19,RBM39UCECEAG7.9785e-05image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr20:35725753-35727011:-ESCAPathEER3.3158e-022.4288e-02-0.3248image
ENSG00000131051.19,RBM39KIRPPathEAG1.3333e-023.9746e-020.1505image
chr20:35728784-35729042:-STADPathEER1.3844e-022.6158e-030.3848image
ENSG00000131051.19,RBM39STADPathEAG4.2781e-021.8470e-020.1360image
ENSG00000131051.19,RBM39THCAPathEAG4.3197e-041.4525e-040.1762image
chr20:35712223-35713652:-THCAPathEER9.6286e-041.4795e-040.1762image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for RBM39


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr20:35712223-35713652:-THCAEERENSG00000124160,NCOA5-0.44263.0911e-205.2809e-24-0.4464imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000141098,GFOD2-0.43405.1541e-209.3115e-22-0.4257imageNAUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr20:35712223-35713652:-THCAEERENSG00000043514,TRIT1-0.43053.0233e-199.4287e-24-0.4441imageNAUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000155252,PI4K2A0.42905.5318e-193.1100e-210.4206imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000162086,ZNF75A-0.41292.7905e-182.1293e-21-0.4222imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000034533,ASTE1-0.41424.1505e-183.2180e-22-0.4300imageNELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000101158,NELFCD-0.41231.0216e-171.2406e-19-0.4047imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr20:35712223-35713652:-THCAEERENSG00000075413,MARK3-0.41091.0983e-174.4346e-20-0.4092imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2MARK3EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000110583,NAA40-0.41161.5706e-171.1578e-20-0.4150imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000276234,TADA2A-0.40841.6272e-172.5968e-21-0.4214imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000124160,NCOA5-0.44263.0911e-205.2809e-24-0.4464imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000141098,GFOD2-0.43405.1541e-209.3115e-22-0.4257imageNAUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr20:35712223-35713652:-THCAEERENSG00000043514,TRIT1-0.43053.0233e-199.4287e-24-0.4441imageNAUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000155252,PI4K2A0.42905.5318e-193.1100e-210.4206imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000162086,ZNF75A-0.41292.7905e-182.1293e-21-0.4222imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000034533,ASTE1-0.41424.1505e-183.2180e-22-0.4300imageNELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000101158,NELFCD-0.41231.0216e-171.2406e-19-0.4047imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr20:35712223-35713652:-THCAEERENSG00000075413,MARK3-0.41091.0983e-174.4346e-20-0.4092imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2MARK3EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000110583,NAA40-0.41161.5706e-171.1578e-20-0.4150imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000276234,TADA2A-0.40841.6272e-172.5968e-21-0.4214imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000124160,NCOA5-0.44263.0911e-205.2809e-24-0.4464imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000141098,GFOD2-0.43405.1541e-209.3115e-22-0.4257imageNAUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr20:35712223-35713652:-THCAEERENSG00000043514,TRIT1-0.43053.0233e-199.4287e-24-0.4441imageNAUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000155252,PI4K2A0.42905.5318e-193.1100e-210.4206imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000162086,ZNF75A-0.41292.7905e-182.1293e-21-0.4222imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000034533,ASTE1-0.41424.1505e-183.2180e-22-0.4300imageNELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000101158,NELFCD-0.41231.0216e-171.2406e-19-0.4047imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr20:35712223-35713652:-THCAEERENSG00000075413,MARK3-0.41091.0983e-174.4346e-20-0.4092imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2MARK3EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000110583,NAA40-0.41161.5706e-171.1578e-20-0.4150imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000276234,TADA2A-0.40841.6272e-172.5968e-21-0.4214imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000124160,NCOA5-0.44263.0911e-205.2809e-24-0.4464imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000141098,GFOD2-0.43405.1541e-209.3115e-22-0.4257imageNAUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr20:35712223-35713652:-THCAEERENSG00000043514,TRIT1-0.43053.0233e-199.4287e-24-0.4441imageNAUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000155252,PI4K2A0.42905.5318e-193.1100e-210.4206imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000162086,ZNF75A-0.41292.7905e-182.1293e-21-0.4222imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000034533,ASTE1-0.41424.1505e-183.2180e-22-0.4300imageNELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000101158,NELFCD-0.41231.0216e-171.2406e-19-0.4047imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr20:35712223-35713652:-THCAEERENSG00000075413,MARK3-0.41091.0983e-174.4346e-20-0.4092imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2MARK3EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000110583,NAA40-0.41161.5706e-171.1578e-20-0.4150imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000276234,TADA2A-0.40841.6272e-172.5968e-21-0.4214imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000124160,NCOA5-0.44263.0911e-205.2809e-24-0.4464imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000141098,GFOD2-0.43405.1541e-209.3115e-22-0.4257imageNAUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr20:35712223-35713652:-THCAEERENSG00000043514,TRIT1-0.43053.0233e-199.4287e-24-0.4441imageNAUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000155252,PI4K2A0.42905.5318e-193.1100e-210.4206imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000162086,ZNF75A-0.41292.7905e-182.1293e-21-0.4222imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000034533,ASTE1-0.41424.1505e-183.2180e-22-0.4300imageNELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000101158,NELFCD-0.41231.0216e-171.2406e-19-0.4047imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr20:35712223-35713652:-THCAEERENSG00000075413,MARK3-0.41091.0983e-174.4346e-20-0.4092imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2MARK3EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000110583,NAA40-0.41161.5706e-171.1578e-20-0.4150imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000276234,TADA2A-0.40841.6272e-172.5968e-21-0.4214imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000124160,NCOA5-0.44263.0911e-205.2809e-24-0.4464imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000141098,GFOD2-0.43405.1541e-209.3115e-22-0.4257imageNAUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr20:35712223-35713652:-THCAEERENSG00000043514,TRIT1-0.43053.0233e-199.4287e-24-0.4441imageNAUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000155252,PI4K2A0.42905.5318e-193.1100e-210.4206imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000162086,ZNF75A-0.41292.7905e-182.1293e-21-0.4222imageNAIFM1;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000034533,ASTE1-0.41424.1505e-183.2180e-22-0.4300imageNELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000101158,NELFCD-0.41231.0216e-171.2406e-19-0.4047imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr20:35712223-35713652:-THCAEERENSG00000075413,MARK3-0.41091.0983e-174.4346e-20-0.4092imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2MARK3EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000110583,NAA40-0.41161.5706e-171.1578e-20-0.4150imageNAIFM1;AUH;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr20:35712223-35713652:-THCAEERENSG00000276234,TADA2A-0.40841.6272e-172.5968e-21-0.4214imageNAIFM1;AUH;DHX9;ELAVL1;HNRNPC;HNRNPUL1;IGF2BP2;LIN28B;NOP58;SLTM;TARBP2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

4. Enriched editing regions and immune related splicing for RBM39


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000131051.19,RBM39
COADEAGIRENSG00000060237.12chr12879572:880999:881691:8817890.22792.7265e-021.0220e-070.4219imageRBM39ACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM39;RBM47;RBM5;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184WNK1EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000131051.19,RBM39
COADEAGA5ENSG00000196262.9chr744799246:44799277:44798747:44798814:44798747:447989040.34071.0879e-031.0894e-120.4778imageRBM39ACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM39;RBM6;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184PPIANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000131051.19,RBM39
COADEAGMEXENSG00000182718.12chr1560386032:60386086:60390212:60390317:60397254:60397338:60397942:603979640.28531.6800e-021.4716e-090.4121imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184ANXA2Dendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000131051.19,RBM39
COADEAGMEXENSG00000113648.12chr5135345967:135346057:135350822:135350913:135352945:135360054:135360496:1353606040.31465.0315e-032.1907e-110.4515imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000131051.19,RBM39
COADEAGMEXENSG00000113648.12chr5135345967:135346057:135350822:135350913:135352945:135353042:135360496:1353606040.31455.0407e-032.1977e-110.4514imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000131051.19,RBM39
COADEAGA3ENSG00000188373.4chr1084176452:84176569:84184850:84185284:84184680:841852840.33804.2043e-045.6058e-200.6146imageNADAR;DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPL;NOP56;NOP58;UPF1NADendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000131051.19,RBM39
COADEAGIRENSG00000058673.11chr1203795653:203796496:203801574:2038016280.33324.6004e-044.7994e-100.4497imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR
ENSG00000131051.19,RBM39
COADEAGIRENSG00000126001.11chr2035472049:35472151:35472672:354727850.23982.4978e-029.4270e-100.4549imageRBM39ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM39;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_PEROXISOME
ENSG00000131051.19,RBM39
COADEAGIRENSG00000107104.14chr9744490:744589:745172:7452210.28721.4168e-026.6701e-140.5008imageRBM39ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM39;RBM5;RBM6;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1KANK1Dendritic_cells_activatedGSVA_HALLMARK_PEROXISOME
ENSG00000131051.19,RBM39
COADEAGA3ENSG00000106077.14chr773738327:73738383:73737645:73738142:73737645:73738072-0.23913.8994e-028.2030e-09-0.4219imageNADAR;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAMacrophages_M0GSVA_HALLMARK_ANDROGEN_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for RBM39


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr20:35712223-35713652:-ACCEERPlasma_cells4.2255e-020.2676image
ENSG00000131051.19,RBM39ACCEAGT_cells_CD4_memory_resting1.3578e-02-0.3119image
chr20:35712223-35713652:-BLCAEERT_cells_CD4_memory_activated1.9568e-040.2163image
ENSG00000131051.19,RBM39BLCAEAGT_cells_CD4_memory_activated5.5670e-040.1919image
chr20:35712223-35713652:-BRCAEERMacrophages_M24.2544e-030.0922image
ENSG00000131051.19,RBM39BRCAEAGDendritic_cells_activated1.3972e-030.1024image
ENSG00000131051.19,RBM39CESCEAGT_cells_CD4_memory_resting5.0099e-03-0.1752image
chr20:35712223-35713652:-CHOLEERDendritic_cells_resting1.8978e-02-0.4125image
ENSG00000131051.19,RBM39CHOLEAGDendritic_cells_resting1.5190e-02-0.4255image
ENSG00000131051.19,RBM39COADEAGMacrophages_M06.7287e-03-0.1915image
ENSG00000131051.19,RBM39DLBCEAGT_cells_CD83.9874e-020.3837image
chr20:35725753-35727011:-ESCAEERT_cells_CD4_memory_activated4.3514e-050.5594image
chr20:35728784-35729042:-ESCAEERDendritic_cells_resting4.2724e-020.3396image
chr20:35736664-35738142:-ESCAEERT_cells_regulatory_(Tregs)1.0015e-03-0.3568image
ENSG00000131051.19,RBM39ESCAEAGT_cells_CD4_memory_activated3.7268e-040.2850image
ENSG00000131051.19,RBM39GBMEAGMacrophages_M05.9085e-04-0.2839image
ENSG00000131051.19,RBM39HNSCEAGNK_cells_resting1.7783e-020.1529image
ENSG00000131051.19,RBM39KICHEAGNK_cells_resting4.2205e-030.4482image
ENSG00000131051.19,RBM39KIRPEAGMacrophages_M18.0799e-040.2284image
ENSG00000131051.19,RBM39LGGEAGMacrophages_M04.5247e-04-0.1613image
chr20:35712223-35713652:-LIHCEERDendritic_cells_activated4.1013e-020.1252image
ENSG00000131051.19,RBM39LIHCEAGNK_cells_activated3.3437e-020.1276image
chr20:35712223-35713652:-LUADEERT_cells_regulatory_(Tregs)2.1572e-030.1509image
ENSG00000131051.19,RBM39LUADEAGT_cells_regulatory_(Tregs)4.7628e-030.1372image
ENSG00000131051.19,RBM39LUSCEAGT_cells_CD4_memory_activated2.6960e-030.1476image
chr20:35712223-35713652:-OVEERT_cells_CD81.2047e-040.2530image
ENSG00000131051.19,RBM39OVEAGT_cells_CD87.1406e-040.2174image
ENSG00000131051.19,RBM39PAADEAGT_cells_CD4_memory_resting1.1559e-02-0.2017image
chr20:35712223-35713652:-PCPGEERT_cells_CD4_memory_resting2.1631e-02-0.1947image
ENSG00000131051.19,RBM39READEAGT_cells_CD4_memory_activated1.0055e-03-0.3747image
chr20:35712223-35713652:-SARCEERT_cells_regulatory_(Tregs)1.6483e-020.1821image
ENSG00000131051.19,RBM39SARCEAGT_cells_regulatory_(Tregs)9.7582e-030.1896image
chr20:35712223-35713652:-SKCMEERT_cells_CD81.7012e-050.2416image
ENSG00000131051.19,RBM39SKCMEAGT_cells_CD83.9813e-050.2251image
chr20:35728784-35729042:-STADEERDendritic_cells_activated1.9401e-020.3011image
chr20:35736664-35738142:-STADEERT_cells_CD4_memory_activated5.0293e-040.2873image
ENSG00000131051.19,RBM39TGCTEAGMacrophages_M25.2851e-04-0.3745image
chr20:35712223-35713652:-THCAEERT_cells_regulatory_(Tregs)2.7684e-040.1684image
ENSG00000131051.19,RBM39THCAEAGT_cells_regulatory_(Tregs)6.6740e-040.1576image
chr20:35712223-35713652:-THYMEERNK_cells_resting9.0199e-030.2708image
ENSG00000131051.19,RBM39THYMEAGNK_cells_resting3.8769e-030.2967image
chr20:35712223-35713652:-UCECEERDendritic_cells_activated4.5400e-030.2484image
ENSG00000131051.19,RBM39UCECEAGDendritic_cells_activated3.3893e-020.1788image
ENSG00000131051.19,RBM39UVMEAGMast_cells_activated1.1330e-020.5410image


Top

6. Enriched editing regions and immune gene sets for RBM39


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr20:35712223-35713652:-BLCAEER4.8991e-02image4.4248e-050.2366image
ENSG00000131051.19,RBM39BLCAEAG3.6007e-02image3.9606e-050.2276image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000131051.19,RBM39STADEAG5.7129e-030.15611.7929e-020.13399.6778e-030.14632.5416e-030.1703image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000131051.19,RBM39ACCGSVA_HALLMARK_APICAL_SURFACEEAG8.9808e-03-0.3292image
chr20:35712223-35713652:-ACCGSVA_HALLMARK_APICAL_SURFACEEER2.0431e-03-0.3968image
chr20:35712223-35713652:-BLCAGSVA_HALLMARK_COMPLEMENTEER2.3021e-080.3197image
ENSG00000131051.19,RBM39BLCAGSVA_HALLMARK_COMPLEMENTEAG8.3173e-080.2941image
chr20:35736664-35738142:-BRCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.6201e-020.5178image
chr20:35712223-35713652:-BRCAGSVA_HALLMARK_PEROXISOMEEER9.8660e-100.1956image
ENSG00000131051.19,RBM39BRCAGSVA_HALLMARK_PEROXISOMEEAG4.7228e-100.1980image
ENSG00000131051.19,RBM39CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4999e-05-0.2674image
chr20:35712223-35713652:-CHOLGSVA_HALLMARK_P53_PATHWAYEER1.2016e-02-0.4387image
ENSG00000131051.19,RBM39CHOLGSVA_HALLMARK_P53_PATHWAYEAG1.3998e-02-0.4302image
ENSG00000131051.19,RBM39COADGSVA_HALLMARK_SPERMATOGENESISEAG2.6862e-06-0.3256image
ENSG00000131051.19,RBM39DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.6294e-02-0.4122image
chr20:35736664-35738142:-ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER5.2668e-030.3054image
chr20:35728784-35729042:-ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER4.9094e-030.4586image
ENSG00000131051.19,RBM39ESCAGSVA_HALLMARK_HYPOXIAEAG4.7727e-040.2800image
chr20:35725753-35727011:-ESCAGSVA_HALLMARK_ANGIOGENESISEER5.8567e-03-0.3960image
ENSG00000131051.19,RBM39GBMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG7.0999e-03-0.2242image
ENSG00000131051.19,RBM39HNSCGSVA_HALLMARK_COMPLEMENTEAG1.5933e-050.2746image
ENSG00000131051.19,RBM39KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.5998e-080.3160image
chr20:35712223-35713652:-KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER5.0487e-090.3299image
ENSG00000131051.19,RBM39KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.8756e-070.3487image
ENSG00000131051.19,RBM39LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.8780e-020.2028image
ENSG00000131051.19,RBM39LGGGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.8318e-080.2528image
ENSG00000131051.19,RBM39LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.7834e-090.3354image
chr20:35712223-35713652:-LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.5366e-070.3145image
chr20:35712223-35713652:-LUADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.6641e-100.3051image
ENSG00000131051.19,RBM39LUADGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG6.2655e-100.2952image
ENSG00000131051.19,RBM39LUSCGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.4393e-060.2351image
ENSG00000131051.19,RBM39MESOGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG3.8628e-020.2410image
chr20:35712223-35713652:-OVGSVA_HALLMARK_DNA_REPAIREER2.4361e-050.2768image
ENSG00000131051.19,RBM39OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.1396e-060.2963image
ENSG00000131051.19,RBM39PAADGSVA_HALLMARK_GLYCOLYSISEAG4.4677e-040.2778image
ENSG00000131051.19,RBM39PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0470e-04-0.3085image
chr20:35712223-35713652:-PCPGGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER3.6119e-040.2983image
ENSG00000131051.19,RBM39PRADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.4961e-040.1866image
ENSG00000131051.19,RBM39READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6725e-020.2576image
ENSG00000131051.19,RBM39SARCGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG3.2957e-050.3002image
chr20:35712223-35713652:-SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.2572e-040.2769image
chr20:35712223-35713652:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0540e-060.2583image
ENSG00000131051.19,RBM39SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6098e-050.2360image
chr20:35736664-35738142:-STADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER5.2577e-070.4050image
chr20:35728784-35729042:-STADGSVA_HALLMARK_SPERMATOGENESISEER3.3957e-020.2743image
ENSG00000131051.19,RBM39STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.2809e-050.2226image
chr20:35725753-35727011:-STADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.6359e-030.3255image
ENSG00000131051.19,RBM39TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.0475e-040.4153image
ENSG00000131051.19,RBM39THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG6.5159e-080.2479image
chr20:35712223-35713652:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER9.0554e-110.2956image
chr20:35712223-35713652:-THYMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3497e-070.5080image
ENSG00000131051.19,RBM39THYMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6785e-070.5108image
chr20:35712223-35713652:-UCECGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.8655e-030.2465image
ENSG00000131051.19,RBM39UCECGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.4572e-040.2808image
ENSG00000131051.19,RBM39UCSGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.7099e-02-0.3494image
ENSG00000131051.19,RBM39UVMGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.6281e-020.5175image


Top

7. Enriched editing regions and drugs for RBM39


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000131051.19,RBM39ACCATRAEAG1.0300e-02-0.3236image
chr20:35712223-35713652:-ACCATRAEER3.5676e-02-0.2764image
chr20:35712223-35713652:-BLCACGP.60474EER1.3826e-06-0.2781image
ENSG00000131051.19,RBM39BLCACGP.60474EAG1.9430e-06-0.2624image
chr20:35736664-35738142:-BRCACEP.701EER7.2578e-03-0.5678image
chr20:35712223-35713652:-BRCAABT.263EER7.6307e-110.2083image
ENSG00000131051.19,RBM39BRCAABT.263EAG2.3406e-110.2126image
ENSG00000131051.19,RBM39CESCGNF.2EAG3.4270e-05-0.2564image
chr20:35712223-35713652:-CHOLJNJ.26854165EER2.6178e-02-0.3928image
ENSG00000131051.19,RBM39CHOLABT.263EAG1.1703e-020.4402image
ENSG00000131051.19,RBM39COADLFM.A13EAG1.1394e-03-0.2290image
ENSG00000131051.19,RBM39DLBCAZD6482EAG2.9775e-020.4111image
chr20:35736664-35738142:-ESCACGP.082996EER7.6468e-06-0.4718image
ENSG00000131051.19,RBM39ESCACGP.60474EAG2.0583e-04-0.2967image
chr20:35728784-35729042:-ESCAGSK.650394EER1.6569e-03-0.5056image
chr20:35725753-35727011:-ESCABIBW2992EER6.7722e-03-0.3897image
ENSG00000131051.19,RBM39GBMBIBW2992EAG7.0719e-04-0.2800image
ENSG00000131051.19,RBM39HNSCCI.1040EAG1.3354e-05-0.2770image
ENSG00000131051.19,RBM39KICHJNK.9LEAG3.4409e-02-0.3396image
ENSG00000131051.19,RBM39KIRCCI.1040EAG1.1254e-03-0.1853image
chr20:35712223-35713652:-KIRCGDC.0449EER1.5270e-04-0.2173image
ENSG00000131051.19,RBM39KIRPBosutinibEAG2.5670e-090.3947image
ENSG00000131051.19,RBM39LAMLGW.441756EAG3.5330e-020.1820image
ENSG00000131051.19,RBM39LGGGSK.650394EAG1.6436e-100.2895image
ENSG00000131051.19,RBM39LIHCDasatinibEAG7.5782e-05-0.2429image
chr20:35712223-35713652:-LIHCCGP.60474EER1.0821e-04-0.2347image
chr20:35712223-35713652:-LUADLenalidomideEER3.6263e-050.2022image
ENSG00000131051.19,RBM39LUADAG.014699EAG2.4703e-050.2037image
ENSG00000131051.19,RBM39LUSCAZ628EAG1.4597e-06-0.2350image
ENSG00000131051.19,RBM39MESOABT.263EAG1.7400e-020.2758image
chr20:35712223-35713652:-OVBAY.61.3606EER1.3297e-040.2515image
ENSG00000131051.19,RBM39OVImatinibEAG2.2168e-040.2367image
ENSG00000131051.19,RBM39PAADBosutinibEAG3.3096e-030.2360image
ENSG00000131051.19,RBM39PCPGJNJ.26854165EAG3.4189e-05-0.3284image
chr20:35712223-35713652:-PCPGBI.D1870EER1.9179e-030.2610image
ENSG00000131051.19,RBM39PRADGNF.2EAG3.4014e-04-0.1831image
chr20:35712223-35713652:-SARCCI.1040EER9.6938e-07-0.3623image
ENSG00000131051.19,RBM39SARCCI.1040EAG3.7780e-07-0.3631image
chr20:35712223-35713652:-SKCMAZD6244EER7.2437e-05-0.2234image
ENSG00000131051.19,RBM39SKCMAZD6244EAG2.2530e-04-0.2026image
chr20:35736664-35738142:-STADImatinibEER3.5147e-030.2426image
ENSG00000131051.19,RBM39STADDocetaxelEAG5.1726e-03-0.1579image
chr20:35725753-35727011:-STADABT.888EER1.0997e-020.2865image
ENSG00000131051.19,RBM39TGCTKIN001.135EAG6.6194e-040.3684image
chr20:35712223-35713652:-THCACI.1040EER1.8668e-12-0.3199image
ENSG00000131051.19,RBM39THCACI.1040EAG5.5797e-12-0.3130image
chr20:35712223-35713652:-THYMBX.795EER2.0355e-070.5103image
ENSG00000131051.19,RBM39THYMEmbelinEAG8.6414e-070.4844image
chr20:35712223-35713652:-UCECMidostaurinEER1.0894e-020.2235image
ENSG00000131051.19,RBM39UCECCGP.60474EAG5.5713e-04-0.2871image
ENSG00000131051.19,RBM39UCSEmbelinEAG2.6137e-020.3515image
ENSG00000131051.19,RBM39UVMFTI.277EAG2.9706e-030.6156image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType